Amgen (NASDAQ:AMGN) today announced that it will hold a conference call
on Wednesday, May 28, 2008, beginning at 8 a.m. Eastern Time to discuss
the results of the denosumab Phase 3 head-to-head study versus
alendronate (the “141”
study) at the upcoming European Symposium on Calcified Tissues (ECTS)
Conference in Barcelona, Spain. Speakers will include the principal
study investigator, Jacques P. Brown, M.D., Head, Division of
Rheumatology, Le Centre hospitalier universitaire de Québec,
and Catherine Stehman-Breen, M.D., Amgen’s
vice president, Global Development – Bone
Therapeutic Area.
Live audio of the conference call will be simultaneously broadcast over
the Internet and will be available to members of the news media,
investors and the general public. The conference call, including the
question and answer session, is expected to last approximately one hour.
The webcast, as with other selected presentations regarding developments
in Amgen’s business given by management at
certain investor and medical conferences, can be found on Amgen’s
Web site, www.amgen.com, under
Investors. Information regarding presentation times, webcast
availability, and webcast links are noted on Amgen’s
Investor Relations Events Calendar. The webcast will be archived and
available for replay 72 hours after the event.
About Amgen
Amgen discovers, develops, manufactures and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realize the new science’s
promise by bringing safe and effective medicines from lab, to
manufacturing plant, to patient. Amgen therapeutics have changed the
practice of medicine, helping millions of people around the world in the
fight against cancer, kidney disease, rheumatoid arthritis, and other
serious illnesses. With a deep and broad pipeline of potential new
medicines, Amgen remains committed to advancing science to dramatically
improve people’s lives. To learn more about
our pioneering science and our vital medicines, visit www.amgen.com.
Amgen, Thousand Oaks
David Polk, 805-447-4613 (media)
Arvind
Sood, 805-447-1060 (investors)
